A new study compares two approaches to improving memory in people with mild cognitive impairment.
Despite the absence of a curative drug, improvements in MCI may be possible though use of substances and tactics published throughout medical journals and summarized here.
UC San Diego researchers have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer’s disease or Mild Cognitive Impairment, a condition that often precedes full-blown dementia.
As yet there is no prescription drug to cure mild cognitive impairment (MCI), often a harbinger of Alzheimer’s disease. Medical research journals reveal curcumin can sometimes bolster cognition. It merits a try.
Although cardiologists often decry coconut oil because of certain fats it contains, they overlook the growing evidence that other fatty constituents, especially medium-chain triglycerides, may alleviate some cases of mild cognitive impairment and Alzheimer’s disease
Mild cognitive impairment affects millions of seniors. There is no curative drug. Seven possibly helpful supplements gleaned from medical journal articles are described
Biogen tried, and failed, to win FDA committee approval for its anti-amyloid Alzheimer’s drug. The Alzheimer’s Association supported the application but did not reveal significant monies received from the firm.
MCI911.com had added a new department, Research Radar, to focus exclusively on advancements to aid fighting MCI
Battling the mild cognitive impairment stage of Alzheimer’s may disease may “nip it in the bud”.
Patients with mild cognitive impairment can aggressively utilize currently available substances and practices to try and delay their brain degeneration
UC San Diego researchers report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer’s disease.
Using sex-specific scores on memory tests may change the diagnosis for 20 percent of those currently diagnosed with mild cognitive impairment (MCI), with possibly more women and fewer men being diagnosed with MCI, according to a new study published online in the journal Neurology.